Why does the Ph. Eur. consider the rFC method as compendial, while the rCR method (which seems closer to the classic LAL test) is still seen as an “alternative method”?
That question had us puzzled for quite a while.
So, to get a better understanding, we asked several experts in the field.
And surprise: there isn’t just one explanation… but two!
We’re sharing both with you, just as we heard them, no judgment. It’s up to you to make up your own mind.
Version 1: More data available for rFC
Historically, the rFC (2003) test was developed before the rCR (2021). So it makes sense that more data has been gathered on this method.
But it is not the only reason why.
Most of the established suppliers were already selling LAL tests. So they had little interest in developing a “competing” method.
All of them? Not quite. One supplier chose a different path: bioMérieux.
Since they didn’t have any LAL solution in their portfolio, they had every reason to promote their recombinant rFC-based test, and they invested heavily in generating supporting data.
As a result, the rFC method got a head start, especially in Europe.
Today, rCR suppliers are slowly closing the gap by producing their own data.
So the “lack of data” argument for rCR might not hold for much longer.
Version 2: A matter of local sovereignty
Horseshoe crabs don’t live everywhere. You’ll mainly find them on the northeast coast of the U.S. — and in some parts of Asia.
In the event of a diplomatic, health, or economic crisis (take, for example, a sudden rise in customs duties), sourcing LAL can quickly become a real challenge.
And without LAL, it’s impossible to release injectable medicines.
To reduce this risk, the EDQM (the organization behind the Ph. Eur.) decided to include recombinant tests starting in 2021.
Why?
Because recombinant reagents can be produced… pretty much anywhere — well, anywhere there’s a manufacturer.
And currently, bioMérieux is the only one producing recombinant reagents in Europe.
That might also help explain why rFC has been prioritized.
And what about the horseshoe crabs?
At first, when we started looking into the world of endotoxins, we naively thought the main goal of recombinant reagents was to protect the horseshoe crabs.
But it turns out that wasn’t really the main driver behind the first regulatory changes.
Conclusion: What’s the future of endotoxin testing?
Everyone we spoke to agrees on one thing:
“The future lies in recombinant tests.”
But a full transition will take time … maybe even several decades.
In the meantime, companies are moving forward… step by step:
- They start by using recombinant methods for water testing,
- then expand to “new” products.
But for products already registered with an LAL test… changes are unlikely to happen anytime soon.
So, what do you think is the real explanation? Version 1, Version 2… or maybe a mix of both?
Here’s an overview of the main recombinant reagent suppliers
Main suppliers of rFC-based recombinant tests:
- bioMerieux (ENDONEXT™)
- Lonza (PyroGene®)
Main suppliers of rCR-based recombinant tests:
- Associates of Cape Cod (PyroSmart NextGen®)
- Charles River ( Endosafe® Trillium™)
- Fujifilm Wako (Pyrostar™ Neo+)